Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

– 24-month apitegromab data from Phase 2 TOPAZ trial presented by Thomas Crawford, M.D.
– Also presenting patient and caregiver observations from real-world evidence study of apitegromab treatment benefits on daily living
-Scholar Rock to host webcast on June 17, 8:30am ET
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA Research and Clinical Care meeting, which …

Read the source article at Home – Neuro Central
2022-06-10 07:00:19